Increased Exhaustion of the Subchondral Bone-Derived Mesenchymal Stem/ Stromal Cells in Primary Versus Dysplastic Osteoarthritis

Čamernik, Klemen; Mihelič, Anže; Mihalič, René; Presen, Darja Marolt; Trebše, Rihard; Marc, Janja; Zupan, Janja

doi:10.1007/s12015-020-09964-x

Cited by 16 publications

(29 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It appears that the exhaustion of physiologically occurring MSCs in patients with primary osteoarthritis occurs. In biomechanical joint damage, subchondral bone populations of MSCs are not impaired [ 54 , 55 , 56 ]. It is also important to establish the ability to proliferate and differentiate, which are key processes in the harvesting of MSCs.…”

Section: Mesenchymal Stem/stromal Cells—origin Cellular and Molecular Characteristics And Signaling Pathways Involved In Differentiationmentioning

confidence: 99%

Mesenchymal Stem/Stromal Cells Derived from Human and Animal Perinatal Tissues—Origins, Characteristics, Signaling Pathways, and Clinical Trials

Kulus

Sibiak

Stefańska

et al. 2021

Cells

View full text Add to dashboard Cite

Mesenchymal stem/stromal cells (MSCs) are currently one of the most extensively researched fields due to their promising opportunity for use in regenerative medicine. There are many sources of MSCs, of which cells of perinatal origin appear to be an invaluable pool. Compared to embryonic stem cells, they are devoid of ethical conflicts because they are derived from tissues surrounding the fetus and can be safely recovered from medical waste after delivery. Additionally, perinatal MSCs exhibit better self-renewal and differentiation properties than those derived from adult tissues. It is important to consider the anatomy of perinatal tissues and the general description of MSCs, including their isolation, differentiation, and characterization of different types of perinatal MSCs from both animals and humans (placenta, umbilical cord, amniotic fluid). Ultimately, signaling pathways are essential to consider regarding the clinical applications of MSCs. It is important to consider the origin of these cells, referring to the anatomical structure of the organs of origin, when describing the general and specific characteristics of the different types of MSCs as well as the pathways involved in differentiation.

show abstract

Section: Mesenchymal Stem/stromal Cells—origin Cellular and Molecular Characteristics And Signaling Pathways Involved In Differentiationmentioning

confidence: 99%

Mesenchymal Stem/Stromal Cells Derived from Human and Animal Perinatal Tissues—Origins, Characteristics, Signaling Pathways, and Clinical Trials

Kulus

Sibiak

Stefańska

et al. 2021

Cells

View full text Add to dashboard Cite

show abstract

“…In humans, the use of autologous or allogeneic cells that are most commonly derived from bone marrow or adipose tissue has reshaped the treatment of debilitating age-associated or injury-inflicted joint disorders. However, there remains substantial concern for the use of autologous cell therapies in patients who already have degenerative disorders, as the regenerative potential of the endogenous MSCs might be impaired or exhausted [ 4 , 5 , 6 , 7 , 8 ]. Degenerative comorbidities and the increasing age of the donor might also have an impact on the quantity of obtainable MSCs [ 6 ].…”

Section: Introductionmentioning

confidence: 99%

Knee and Peri-Knee Tissues of Post Mortem Donors Are Strategic Sources of Mesenchymal Stem/Stromal Cells for Regenerative Procedures

Haring

Zupan

2022

IJMS

Self Cite

View full text Add to dashboard Cite

Tissues of post mortem donors represent valuable alternative sources for the isolation of primary cells with mesenchymal stem/stromal cell (MSC)-like properties. However, the properties of primary cells derived from different tissues and at different post mortem times are poorly recognized. Here, we aim to identify the optimal tissue source between three knee and peri-knee tissues for the isolation of primary cells with MSC-like properties, and to define the influence of the time post mortem on the properties of these cells. We harvested tissues from subchondral bone marrow, synovium and periosteum from 32 donors at various post mortem times. Primary cells were evaluated using detailed in vitro analyses, including colony formation, trilineage differentiation, immunophenotyping and skeletal stem cell marker-gene expression profiling. These data show that the primary cells with MSC-like properties isolated from these three tissues show no differences in their properties, except for higher expression of CD146 in bone-marrow cells. The success rate of the primary cell isolation is dependent on the post mortem time. However, synovium and periosteum cells isolated more than 48 h post mortem show improved osteogenic and chondrogenic potential. This study suggests that knee and peri-knee tissues from donors even 3 days post mortem are strategic sources of MSCs for regenerative procedures.

show abstract

“…In a recent study, Klemen Čamernik et al provided new scientific knowledge for the pathophysiological mechanisms of primary osteoarthritis (OA) in relation to mesenchymal stromal cells (MSCs) features. The authors reported that the exhaustion of MSCs may be implicated in the pathogenesis of OA (1). As evoked by the authors, medicinal approaches that target exhausted or impaired MSCs might provide new promise for future treatments.…”

mentioning

confidence: 98%

“…These subchondral MSCs were exhausted and presented altered differential potential. Indeed, they showed lower viability, altered osteogenesis and chondrogenesis as well as lower expression of the leptin receptor (LepR) [1]. As known, LepR is a marker of quiescent MSCs that proliferate regenerate bone after injury [11].…”

mentioning

confidence: 99%

See 1 more Smart Citation

Of Mesenchymal Stem/Stromal Cells and Osteoarthritis: Time to Merge the Latest Breakthroughs

Najar

Fahmi

2020

Stem Cell Rev and Rep

View full text Add to dashboard Cite

Osteoarthritis (OA) is a degenerative joint disease of the articular cartilage with subchondral bone remodeling and synovial inflammation. There is currently no cure for OA, making effective management extremely challenging. During the last years, significant advances has been made to develop regenerative medicine based on the use of stem cells as alternative for treating OA. Because of their several advantages including availability, expandability, transplantability, and ethical implications. mesenchymal stem/stromal cells (MSCs) appear thus to be a promising tool for the field. Based on the recent paper of Klemen Čamernik et al. in Stem Cell Reviews and Reports, we highlighted some challenges and possible strategies to enhance the therapeutic potential of MSCs for OA.

show abstract

Increased Exhaustion of the Subchondral Bone-Derived Mesenchymal Stem/ Stromal Cells in Primary Versus Dysplastic Osteoarthritis

Cited by 16 publications

References 32 publications

Mesenchymal Stem/Stromal Cells Derived from Human and Animal Perinatal Tissues—Origins, Characteristics, Signaling Pathways, and Clinical Trials

Mesenchymal Stem/Stromal Cells Derived from Human and Animal Perinatal Tissues—Origins, Characteristics, Signaling Pathways, and Clinical Trials

Knee and Peri-Knee Tissues of Post Mortem Donors Are Strategic Sources of Mesenchymal Stem/Stromal Cells for Regenerative Procedures

Of Mesenchymal Stem/Stromal Cells and Osteoarthritis: Time to Merge the Latest Breakthroughs

Contact Info

Product

Resources

About